Profile data is unavailable for this security.
About the company
Aarti Pharmalabs Limited is a manufacturer of active pharmaceutical ingredients (API), pharmaceutical intermediates, new chemical entities (NCE), xanthine derivatives, and allied products, situated in India. The Company delivers contract development and manufacturing organization (CDMO) services for drug substance/NCE development and manufacturing for pharmaceutical and biotech firms with a focus on the Ph-I/II/III, launch, and commercial phases. It has dedicated facilities for the production of corticosteroids, cytotoxic medicines, and oncology products. Its range of API products include Ramipril, Quinapril HCL, Budesonide, Bambuterol HCL, Apixaban, Rivaroxaban, Cinacalcet and others. Its range of intermediate products include Abemaciclib Intermediate, Acalabrutinib Intermediate, Afatinib Intermediate, Apalutamide Intermediate, Azathioprine Intermediate, and others. Its Caffeine products include caffeine anhydrous, and caffeine anhydrous (granules).
- Revenue in INR (TTM)19.68bn
- Net income in INR2.28bn
- Incorporated2019
- Employees1.63k
- LocationAarti Pharmalabs LtdMUMBAI 400080IndiaIND
- Phone+91 2 269436100
- Fax+91 2 267976660
- Websitehttps://www.aartipharmalabs.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RPG Life Sciences Limited | 6.18bn | 706.60m | 37.32bn | 1.27k | 52.82 | 9.84 | 41.52 | 6.04 | 42.72 | 42.72 | 373.86 | 229.38 | 1.22 | 1.99 | 8.44 | 4,868,662.00 | 13.92 | 16.07 | 19.35 | 21.77 | 67.85 | 62.99 | 11.43 | 11.99 | 1.45 | 207.32 | 0.00 | 29.27 | 13.50 | 12.01 | 29.60 | 51.98 | 28.60 | 46.14 |
| Solara Active Pharma Sciences Ltd | 12.22bn | -5.36bn | 42.36bn | 2.16k | -- | 2.52 | -- | 3.47 | -137.13 | -137.13 | 320.29 | 301.63 | 0.4731 | 1.77 | 2.69 | 5,667,023.00 | -20.76 | -2.44 | -36.40 | -3.84 | 38.70 | 41.16 | -43.89 | -4.49 | 0.448 | -1.30 | 0.4355 | -- | -10.73 | -1.45 | -2,458.12 | -- | -4.81 | -- |
| Aarti Drugs Ltd | 23.80bn | 1.52bn | 43.45bn | 1.06k | 28.64 | 3.40 | 21.13 | 1.83 | 16.62 | 16.62 | 259.74 | 139.96 | 0.9954 | 3.16 | 3.43 | 22,364,630.00 | 6.37 | 9.73 | 9.62 | 15.78 | 34.60 | 22.23 | 6.40 | 8.25 | 1.01 | 6.83 | 0.3159 | -- | -6.90 | 10.13 | 3.07 | 13.82 | 24.96 | -- |
| Morepen Laboratories Ltd | 17.45bn | 1.18bn | 43.73bn | 1.62k | 34.54 | -- | 29.23 | 2.51 | 2.31 | 2.31 | 34.26 | -- | -- | -- | -- | 10,749,300.00 | -- | 7.90 | -- | 13.34 | 37.86 | 33.34 | 6.77 | 5.49 | -- | 33.34 | -- | 0.00 | 19.25 | 17.08 | 148.63 | 27.22 | 47.03 | -- |
| Jeena Sikho Lifecare Ltd | -100.00bn | -100.00bn | 44.58bn | 1.23k | -- | 141.00 | -- | -- | -- | -- | -- | 12.72 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.8228 | -- | 0.2681 | -- | 43.84 | -- | 77.37 | -- | -- | -- |
| Gufic BioSciences Ltd | 8.14bn | 863.69m | 45.25bn | 1.45k | 51.88 | -- | 43.74 | 5.56 | 8.70 | 8.70 | 81.95 | -- | -- | -- | -- | 5,624,707.00 | -- | 11.46 | -- | 19.21 | 52.39 | 45.79 | 10.60 | 10.46 | -- | 8.09 | -- | 1.31 | 16.80 | 18.12 | 8.07 | 31.46 | 53.83 | 14.87 |
| Hikal Ltd | 18.03bn | 677.82m | 47.43bn | 2.06k | 70.01 | -- | 25.03 | 2.63 | 5.49 | 5.49 | 145.97 | -- | -- | -- | -- | 8,749,879.00 | -- | 5.07 | -- | 7.51 | 53.06 | 46.78 | 3.76 | 5.86 | -- | 2.45 | -- | 12.19 | -11.79 | 2.34 | -11.20 | -7.55 | 9.72 | 0.00 |
| Supriya Lifescience Ltd | 6.25bn | 1.58bn | 51.34bn | 448.00 | 32.64 | 5.67 | 29.37 | 8.21 | 19.54 | 19.54 | 77.55 | 112.56 | 0.6737 | 2.01 | 6.56 | 13,950,510.00 | 16.98 | 19.08 | 18.38 | 24.04 | 66.81 | 57.12 | 25.20 | 24.71 | 4.05 | 111.46 | 0.006 | 2.88 | 23.74 | 15.47 | 32.56 | 24.75 | 83.79 | -- |
| SeQuent Scientific Ltd | 14.27bn | 54.87m | 51.43bn | 1.20k | 965.27 | -- | 66.20 | 3.60 | 0.2137 | 0.2137 | 57.18 | -- | -- | -- | -- | 11,939,190.00 | -- | 1.09 | -- | 1.76 | 45.38 | 41.97 | 0.9902 | 1.18 | -- | 0.9009 | -- | 35.06 | -3.60 | 5.68 | 70.40 | -- | 6.96 | -- |
| Innova Captab Ltd | 11.78bn | 1.18bn | 54.60bn | -- | 38.10 | 6.10 | 39.99 | 4.64 | 25.04 | 25.04 | 232.86 | 156.45 | 0.903 | 4.83 | 3.74 | -- | 9.07 | 10.82 | 12.50 | 18.38 | 34.06 | 25.18 | 10.05 | 8.04 | 1.32 | 19.79 | 0.2259 | -- | 16.72 | 24.90 | 38.84 | 36.55 | 104.14 | -- |
| Aarti Pharmalabs Ltd | 19.68bn | 2.28bn | 59.33bn | 1.63k | 26.02 | 3.20 | 19.32 | 3.01 | 25.16 | 25.16 | 217.12 | 204.88 | 0.7733 | 1.62 | 4.59 | 12,095,750.00 | 8.96 | -- | 11.86 | -- | 45.56 | -- | 11.59 | -- | 0.9611 | 17.12 | 0.1723 | -- | -4.76 | -- | 12.10 | -- | -- | -- |
| Unichem Laboratories Ltd | 17.28bn | -605.50m | 61.75bn | 3.19k | -- | -- | 118.19 | 3.57 | -8.59 | -8.59 | 245.15 | -- | -- | -- | -- | 5,410,587.00 | -- | -1.67 | -- | -2.03 | 62.00 | 56.18 | -3.50 | -3.99 | -- | 0.1401 | -- | -- | 26.94 | 7.64 | 65.15 | -- | -35.00 | -- |
| Sun Pharma Advanced Research Co Ltd | 600.85m | -4.09bn | 66.65bn | 409.00 | -- | -- | -- | 110.92 | -12.60 | -12.60 | 1.85 | -2.38 | 0.1216 | -- | 2.66 | 1,469,078.00 | -82.71 | -61.70 | -164.56 | -119.31 | 51.18 | 74.49 | -680.16 | -163.40 | -- | -145.15 | 4.25 | -- | -68.36 | -16.21 | -73.96 | -- | 15.40 | -- |
| Orchid Pharma Ltd | 8.81bn | 1.12bn | 75.15bn | 872.00 | 64.74 | -- | 51.28 | 8.53 | 22.89 | 22.89 | 180.65 | -- | -- | -- | -- | 10,101,540.00 | -- | -0.9734 | -- | -1.40 | 40.67 | 40.74 | 12.78 | -2.40 | -- | 6.08 | -- | -- | 23.05 | 6.43 | 73.59 | 5.84 | 57.79 | -- |
| F D C Ltd | 20.72bn | 3.17bn | 81.19bn | 6.66k | 25.76 | 3.54 | 22.44 | 3.92 | 19.36 | 19.36 | 126.27 | 140.76 | 0.824 | 2.16 | 12.48 | 3,112,058.00 | 12.59 | 12.05 | 14.46 | 13.73 | 65.35 | 61.54 | 15.27 | 15.85 | 2.49 | 72.53 | 0.0087 | 1.09 | 8.92 | 12.24 | 57.30 | 12.45 | 16.93 | -- |
Data as of Nov 13 2024. Currency figures normalised to Aarti Pharmalabs Ltd's reporting currency: Indian Rupee INR
7.07%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| quant Money Managers Ltd.as of 31 Oct 2024 | 2.94m | 3.25% |
| Morgan Stanley Investment Management Co.as of 30 Sep 2024 | 909.59k | 1.00% |
| BlackRock Fund Advisorsas of 03 Oct 2024 | 733.29k | 0.81% |
| Dimensional Fund Advisors LPas of 03 Oct 2024 | 551.81k | 0.61% |
| HDFC Asset Management Co. Ltd. (Invt Mgmt)as of 30 Sep 2024 | 496.33k | 0.55% |
| Norges Bank Investment Managementas of 30 Jun 2024 | 341.87k | 0.38% |
| BlackRock Advisors (UK) Ltd.as of 03 Oct 2024 | 135.89k | 0.15% |
| Motilal Oswal Asset Management Co. Ltd.as of 31 Oct 2024 | 110.50k | 0.12% |
| Mellon Investments Corp.as of 03 Oct 2024 | 103.68k | 0.11% |
| American Century Investment Management, Inc.as of 31 Oct 2024 | 77.17k | 0.09% |
More ▼
Data from 30 Jun 2024 - 31 Oct 2024Source: FactSet Research Systems Inc.
